A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
NCT 06422520 Brief Summary This is a first-in-human, Phase 1a/1b study to…
Read more arrow_forwardNCT 06422520 Brief Summary This is a first-in-human, Phase 1a/1b study to…
Read more arrow_forwardACTRN 12623000108617 Brief Summary This study aims to assess a new cancer…
Read more arrow_forwardNCT 07016490 Brief Summary This study is an open-label phase I study…
Read more arrow_forwardACTRN 12622000993796 Brief Summary AXA-042 functions through a multi-cellular mechanism to re-engage…
Read more arrow_forwardACTRN 12623000956606 Brief Summary This study will be conducted in two parts…
Read more arrow_forwardNCT 06384352 Brief Summary This is a multicenter, open-label, Phase 1 study.…
Read more arrow_forwardACTRN 12623000307606 Brief Summary This study is investigating a new cancer treatment…
Read more arrow_forwardACTRN 12622001339741 Brief Summary This is a first in human study of…
Read more arrow_forwardNCT 06532006 Brief Summary This is a double-blind, randomized, multiregion, comparative phase…
Read more arrow_forwardNCT 06764875 Brief Summary This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded,…
Read more arrow_forward